Jing-Xin Li

InstitutionJiangsu provincial Center for Disease Control and Prevention
AddressNanjing
Jiangsu
China
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 8 Covid-19 publications, with a maximum of 1 publications in May 2020 and July 2020 and November 2020 and March 2021 and April 2021 and May 2021 and July 2021 and August 2021
    All Publications
    Bar chart showing 51 publications over 15 distinct years, with a maximum of 10 publications in 2015
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Jiang HD, Tao YY, Jia SY, Li JX, Zhu FC. Coronavirus disease 2019 vaccines: landscape of global studies and potential risks. Chin Med J (Engl). 2021 Aug 02; 134(17):2037-2044. PMID: 34343152.
      Citations:    Fields:    Translation:Humans
    2. Meng FY, Gao F, Jia SY, Wu XH, Li JX, Guo XL, Zhang JL, Cui BP, Wu ZM, Wei MW, Ma ZL, Peng HL, Pan HX, Fan L, Zhang J, Wan JQ, Zhu ZK, Wang XW, Zhu FC. Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Signal Transduct Target Ther. 2021 07 15; 6(1):271. PMID: 34267185.
      Citations: 1     Translation:HumansCTClinical Trials
    3. Jiang HD, Zhang L, Li JX, Zhu FC. Next Steps for Efficacy Evaluation in Clinical Trials of COVID-19 Vaccines. Engineering (Beijing). 2021 Jul; 7(7):903-907. PMID: 34123472.
      Citations:    
    4. Pan HX, Liu JK, Huang BY, Li GF, Chang XY, Liu YF, Wang WL, Chu K, Hu JL, Li JX, Zhu DD, Wu JL, Xu XY, Zhang L, Wang M, Tan WJ, Huang WJ, Zhu FC. Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chin Med J (Engl). 2021 Apr 28; 134(11):1289-1298. PMID: 33928916.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    5. Li JX, Zhu FC. Adjuvantation helps to optimise COVID-19 vaccine candidate. Lancet Infect Dis. 2021 07; 21(7):891-893. PMID: 33705726.
      Citations: 5     Fields:    Translation:Humans
    6. Chen XJ, Li K, Xu L, Yu YJ, Wu B, He YL, Zhao WE, Li D, Luan CX, Hu L, Wang J, Ding JJ, Yu YF, Li JX, Tan ZM, Liu XF, Wei D, Zhang ZH, Guo XJ, Su C, Hu ZB, Guo YS, Chen JY, Chen F. Novel insight from the first lung transplant of a COVID-19 patient. Eur J Clin Invest. 2021 Jan; 51(1):e13443. PMID: 33131070.
      Citations: 6     Fields:    Translation:HumansCells
    7. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XW, Wang XH, Chen W. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 08 15; 396(10249):479-488. PMID: 32702299.
      Citations: 361     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    8. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 06 13; 395(10240):1845-1854. PMID: 32450106.
      Citations: 442     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials